• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cue Biopharma Inc.

    8/12/25 4:11:48 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CUE alert in real time by email
    S-8 1 cue-20250812.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on August 12, 2025

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Cue Biopharma, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

     

     

    Delaware

    47-3324577

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

     

    40 Guest Street

    Boston, MA

    02135

    (Address of principal executive offices)

    (Zip Code)

    2025 Stock Incentive Plan

    (Full title of the plan)

    Daniel R. Passeri

    Chief Executive Officer

     

    Cue Biopharma, Inc.

    40 Guest Street

    Boston, MA 02135

    (Name and address of agent for service)

    (617) 949-2680

    (Telephone number, including area code, of agent for service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information.

    The information required by Item 1 is omitted from this registration statement and included in documents sent or given to participants in the plan covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”) and the Note to Part I of Form S-8.

    Item 2. Registrant Information and Employee Plan Annual Information.

    The written statement required by Item 2 is omitted from this registration statement and included in documents sent or given to participants in the plan covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act and the Note to Part I of Form S-8.

     

     


     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

    The Registrant is subject to the informational and reporting requirements of Sections 13(a), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the “Commission”). The following documents, which are on file with the Commission, are incorporated in this registration statement by reference:

    (a)
    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Commission on March 31, 2025, including the information specifically incorporated by reference into the Annual Report on Form 10-K from the Registrant’s definitive proxy statement for the 2025 Annual Meeting of Stockholders;
    (b)
    The Registrant’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025 and June 30, 2025, as filed with the Commission on May 12, 2025 and August 12, 2025, respectively;
    (c)
    The Registrant’s Current Reports on Form 8-K as filed with the Commission on March 12, 2025, April 14, 2025, April 15, 2025 (excluding Item 2.02), June 10, 2025 and July 1, 2025; and
    (d)
    The description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A, as filed with the Commission on December 13, 2017, as the description therein has been updated and superseded by the description of the Registrant’s capital stock contained in Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Commission on March 31, 2025, and including any amendments and reports filed for the purpose of updating such description.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    The following summary is qualified in its entirety by reference to the complete Delaware General Corporation Law (the “DGCL”) and the Registrant’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”) and the Registrant’s Amended and Restated Bylaws.

    Section 145 of the DGCL provides, generally, that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (except actions by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation against all expenses, judgments, fines and amounts paid in

     


     

    settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may similarly indemnify such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation, provided that a court shall have determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.

    Section 102(b)(7) of the DGCL provides, generally, that the Certificate of Incorporation may contain a provision eliminating or limiting the personal liability of a director or officer to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, provided that such provision may not eliminate or limit the liability of (i) a director or officer for any breach of the director’s or officer’s duty of loyalty to the corporation or its stockholders, (ii) a director or officer for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) a director under section 174 of the DGCL, (iv) a director or officer for any transaction from which the director or officer derived an improper personal benefit, or (v) an officer in any action by or in the right of the corporation. No such provision may eliminate or limit the liability of a director or officer for any act or omission occurring prior to the date when such provision became effective.

    Article VI of the Certificate of Incorporation states that the Registrant’s directors shall not be personally liable to the Registrant or to its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability. Under Section 102(b)(7) of the DGCL, the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty can be limited or eliminated except (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders; (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) under Section 174 of the DGCL (relating to unlawful payment of dividend or unlawful stock purchase or redemption); or (iv) for any transaction from which the director derived an improper personal benefit.

    Article V of the Certificate of Incorporation provides that the Registrant shall indemnify (and advance expenses to) its officers and directors to the full extent permitted by the DGCL.

    The Registrant has directors’ and officers’ liability insurance insuring its directors and officers against liability for acts or omissions in their capacities as directors or officers, subject to certain exclusions. Such insurance also insures the Registrant against losses which it may incur in indemnifying its officers and directors. As permitted by the DGCL, the Registrant has entered into indemnification agreements with each of its directors and executive officers that require the Registrant to indemnify such persons against various actions including, but not limited to, third-party actions where such director or executive officer, by reason of his or her corporate status, is a party or is threatened to be made a party to an action, or by reason of anything done or not done by such director in any such capacity. The Registrant intends to indemnify directors and executive officers against all costs, judgments, penalties, fines, liabilities, amounts paid in settlement by or on behalf of such directors or executive officers and for any expenses actually and reasonably incurred by such directors or executive officers in connection with such action, if such directors or executive officers acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the Registrant, and with respect to any criminal proceeding, had no reasonable cause to believe their conduct was unlawful. The Registrant also intends to advance to its directors and executive officers’ expenses (including attorney’s fees) incurred by such directors and executive officers in advance of the final disposition of any action after the receipt by the Registrant of a statement or statements from directors or executive officers requesting such payment or payments from time to time, provided that such statement or statements are accompanied by an undertaking, by or on behalf of such directors or executive officers, to repay such amount if it shall ultimately be determined that they are not entitled to be indemnified against such expenses by the Registrant.

    The indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification or advancement of expenses, including, among others, provisions about providing notice to the Registrant of any action in connection with which a director or executive officer seeks indemnification or

     


     

    advancement of expenses from the Registrant and provisions concerning the determination of entitlement to indemnification or advancement of expenses.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    The following exhibits are incorporated herein by reference:

     

     

     

    Number

    Description

     

     

      4.1

    Amended and Restated Certificate of Incorporation, as amended, of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38327) filed with the Securities and Exchange Commission on August 12, 2025)

     

     

      4.2

    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.5 to the Registrant’s Registration Statement on Form S-1 (File No. 333-220550) filed with the Securities and Exchange Commission on December 5, 2017)

     

     

      5.1*

    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant

     

     

    23.1*

    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)

     

     

    23.2*

    Consent of RSM US LLP, Independent Registered Public Accounting Firm

     

     

    24.1*

    Power of attorney (included on the signature pages of this registration statement)

     

     

    99.1

    Cue Biopharma, Inc. 2025 Stock Incentive Plan (incorporated by reference to Exhibit 99.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38327) filed with the Securities and Exchange Commission on June 10, 2025)

     

     

    107*

     

    Calculation of Filing Fee Tables

     

     

     

     

    * Filed herewith.

     


     

    Item 9. Undertakings.

    1.
    The undersigned registrant hereby undertakes:
    a.
    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
    i.
    To include any prospectus required by Section 10(a)(3) of the Securities Act;
    ii.
    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” in the effective registration statement; and
    iii.
    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    provided, however, that paragraphs (i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

    b.
    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    c.
    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    2.
    The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    3.
    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on this 12th day of August, 2025.

     

     

     

    CUE BIOPHARMA, INC.

     

     

    By:

    /s/ Daniel R. Passeri

     

    Daniel R. Passeri

     

    Chief Executive Officer

     

     


     

    POWER OF ATTORNEY AND SIGNATURES

    We, the undersigned officers and directors of Cue Biopharma, Inc., hereby severally constitute and appoint Daniel R. Passeri, Lucinda Warren and Colin Sandercock, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Cue Biopharma, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

     

     

    Signature

    Title

    Date

     

     

     

    /s/ Daniel R. Passeri

    Daniel R. Passeri

    Chief Executive Officer and

    Director

    (Principal executive, financial and accounting officer)

    August 12, 2025

     

     

     

    /s/ Jill Broadfoot

    Jill Broadfoot

    Director

     

    August 12, 2025

     

     

     

     

    /s/ Pamela Garzone

    Pamela Garzone

    Director

    August 12, 2025

     

     

     

     

     

     

    /s/ Patrick Verheyen

     

    Director

     

    August 12, 2025

    Patrick Verheyen

     

     

     

     

     

     

     

     

    /s/ Peter Kiener

     

    Director

     

    August 12, 2025

    Peter Kiener

     

     

     

     

     

     

     

     

    /s/ Frank Morich

     

    Director

     

    August 12, 2025

    Frank Morich

     

     

     

     

     

     

     

     

    /s/ Pasha Sarraf

     

    Director

     

    August 12, 2025

    Pasha Sarraf

     

     

     

     

     

     

     

     

     

     


    Get the next $CUE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CUE

    DatePrice TargetRatingAnalyst
    3/13/2024$6.00Buy
    Jefferies
    6/26/2023$10.00Outperform
    Oppenheimer
    11/21/2022$7.00Overweight
    Piper Sandler
    1/13/2022$20.00Buy
    H.C. Wainwright
    1/3/2022$28.00Buy
    Craig Hallum
    More analyst ratings

    $CUE
    SEC Filings

    View All

    SEC Form S-8 filed by Cue Biopharma Inc.

    S-8 - Cue Biopharma, Inc. (0001645460) (Filer)

    8/12/25 4:11:48 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Cue Biopharma Inc.

    10-Q - Cue Biopharma, Inc. (0001645460) (Filer)

    8/12/25 4:00:53 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cue Biopharma, Inc. (0001645460) (Filer)

    8/12/25 4:00:29 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Broadfoot Jill Marie

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    6/6/25 4:00:05 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Broadfoot Jill Marie

    3 - Cue Biopharma, Inc. (0001645460) (Issuer)

    6/6/25 4:00:04 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CHIEF FINANCIAL OFFICER Millar Kerri-Ann

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    3/25/25 4:00:10 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Cue Biopharma with a new price target

    Jefferies initiated coverage of Cue Biopharma with a rating of Buy and set a new price target of $6.00

    3/13/24 7:30:48 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Cue Biopharma with a new price target

    Oppenheimer resumed coverage of Cue Biopharma with a rating of Outperform and set a new price target of $10.00

    6/26/23 7:24:09 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Cue Biopharma with a new price target

    Piper Sandler initiated coverage of Cue Biopharma with a rating of Overweight and set a new price target of $7.00

    11/21/22 7:39:31 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

    First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, announced today the initiation of an investigator sponsored trial (IST) in rGBM at the DFCI with the first patient in the trial having been dosed with CUE-102. The trial (NCT06917885) is a Phase 1b, open-label study of adjuvant CUE-102, the Company's drug product candidate targeting Wilms' Tumor 1

    8/13/25 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

    Received FDA feedback on Pre-IND Briefing Document reinforcing Company's intention to advance investigational new drug (IND) submission for CUE-401 to address unmet need in the treatment of autoimmune disease. Announced strategic research collaboration and license agreement with Boehringer Ingelheim to develop and commercialize CUE-501, a differentiated B cell depletion therapy for autoimmune and inflammatory diseases. Upfront payment of $12 million and ~$345 million in potential milestone payments Raised approximately $20 million through a public offering. BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage bio

    8/12/25 4:05:00 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 23, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts to U.S. research budgets could stall progress in prevention and treatment. Adding to the strain, federal and state regulators are re‑examining mRNA vaccines, creating a cloud of uncertainty over future cancer‑funding priorities. Yet even amid this policy turbulence, a new wave of oncology innovators is lining up near‑term milestones that could reshape the landscape—led by Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Cue Biopharma, Inc. (NASDAQ:CUE)

    7/23/25 9:26:00 AM ET
    $ALLO
    $CATX
    $CUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $CUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Passeri Daniel R bought $30,900 worth of shares (30,000 units at $1.03), increasing direct ownership by 22% to 164,578 units (SEC Form 4)

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    12/18/24 4:00:04 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Leadership Updates

    Live Leadership Updates

    View All

    Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

    BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the appointment of industry veteran Lucinda Warren as chief business officer (CBO). With an extensive background and proven expertise in strategic transactions, portfolio optimization and alliance management through her extensive tenure at Johnson & Johnson and Jansen, Ms. Warren will play a pivotal role in advancing Cue Biopharma's core corporate objectives following the company's recent business restructuring and autoimmune program prioritizati

    9/9/24 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors

    BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today the appointment of seasoned pharmaceutical executive Pamela D. Garzone, Ph.D., to its board of directors. Dr. Garzone brings to Cue Biopharma more than 25 years of healthcare and pharmaceutical industry experience in drug development, including strategic, scientific, clinical and regulatory leadership expertise. "We are pleased to have Dr. Garzone join our board of directors," said Daniel Passeri, chief executive

    4/25/23 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

    BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today the appointment of industry veteran Patrick Verheyen to its board of directors (BOD). Mr. Verheyen brings to Cue Biopharma more than 35-years of experience facilitating pipeline growth and innovation programs at Janssen Pharmaceutical Companies of Johnson and Johnson. "We are very pleased to welcome Mr. Verheyen to our BOD and leverage his extensive experience and guidance as we seek to enhance and broaden Cue Bi

    4/12/23 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Financials

    Live finance-specific insights

    View All

    Cue Biopharma to Host Business Update Call and Webcast

    BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET. Conference Call and Webcast DetailsTuesday, April 15 at 4:30 p.m. ET Investors:1-844-826-3035International Investors:1-412-317-5195Conference ID:10199037Webcast Link:https://viavid.webcasts.com/starthere.jsp?ei=1715808&tp_key=9378826572 The live and archived webcast will also b

    4/14/25 5:02:00 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma to Host Business Update Call and Webcast

    BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, August 19, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The company will provide a business overview of its recent restructuring and near-term strategic prioritization objectives. The discussion will focus on the company's approach to enhance near-term shareholder value by refocusing resourc

    8/13/24 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma to Host Business Update Call and Webcast

    BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The Company will provide a corporate update highlighting measurable progress advancing its lead clinical oncology programs, CUE-101 and CUE-102, its lead preclinical autoimmune program CUE-401 partnered with Ono Pharmaceutical, as well as additional au

    4/2/24 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cue Biopharma Inc.

    SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

    3/11/24 6:40:41 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cue Biopharma Inc.

    SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

    2/7/24 5:09:04 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cue Biopharma Inc.

    SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

    1/31/24 2:08:28 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care